维生素A酸

产品编号	英文名称	CAS号	包装
Y0744	Retinoic acid	302-79-4	可根据客户要求订制

产品编号：Y0744

英文名称：Retinoic acid

CAS号 302-79-4

分析标准品

分子式 C20H28O2 分子量300.44

基本信息:

 

密度1.011

熔点180-181°C

存贮条件储存温度：-20°C

描述

产品介绍不溶于水，溶于乙醚、DMSO (25 mg/ml)；微溶于乙醇和氯仿。

别名维生素A酸 ;维A酸;all-trans-Retinoic acid ATRA Tretinoin Vitamin A acid

生化机理

Description: IC50 Value: N/A All-trans retinoic acid (ATRA) has been widely investigated for treatments of many cancers including prostate cancer. in vitro: ATRA was able to induce the growth arrest and to increase HOXB13 expression in ARprostate cancer cells. Both EZH2 and DNMT3b participated in the repression of HOXB13 expression through an epigenetic mechanism involving DNA and histone methylation modifications[1]. ATRA could upregulate HOXB13 through decreasing EZH2 and DNMT3b expressions and reducing their interactions with the HOXB13 promoter[1]. in vivo: Earlier studies revealed that treatment of leukemic cells with ATRA resulted in the apoptosis, presumably secondary to the differentiation process. Since ATRA can rectify aberrant cell growth and induce apoptosis, it has been widely investigated in preclinical and clinical trials for the treatment of many cancer types, including early gastric cancer and prostate cancer . In AR and drug resistant DU145 prostate cancer cells, ATRA was demonstrated to increase the sensitivity of cells to anticancer agent docetaxel[1]. All-trans retinoic acid (ATRA) induces clinical remission in APL patients by enhancing the rapid differentiation of APL cells and the clearance of PML-RARα, APL's hallmark oncoprotein[2]. Clinical trial: N/A

应用维生素A酸(ATRA) 是一种维生素A酸受体(RAR)和Retinoid X 受体(RXR)的配体，结合上RAR 和 RXR作为转导因子，调控正常细胞和肿瘤细胞的生长和分化。细胞色素P450 (CYPs) 催化ATRA的羟基化；维生素A酸引导胚胎干细胞(embryonic stem cells) 演变成神经元。